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Few subjects capture the imagination more than how humans grow and develop. The apparent 
biological simplicity of two cells coming together belies the enormously complex and highly regulated 
changes that will result in a fetus and newborn. The link between our physical development into what 
makes us who we are, with the behavioral, cognitive, and emotional changes we experience during 
our lifetime, are of course shaped by innumerable factors – our genes, our environment, education 
and cultural milieu. But it is also increasingly clear that our short “start in life” – just 280 or so days of 
intra-uterine existence - has a profound effect on our subsequent chances of healthy development.  
 
As clinicians, monitoring growth is an essential part of care and aims to determine if there are growth 
abnormalities that may signify underlying nutritional disorders or disease; and to take steps to reduce 
related morbidity and mortality. Given the enormity of the subject area, it is natural to break this up 
into epochs of development, and in this issue leading experts consolidate the latest evidence 
regarding diagnosis and management of aberrations of fetal growth. Nevertheless, it must be 
remembered at all times that human development is a continuum. Recent progress towards a fully 
integrative approach to monitoring growth and development from early pregnancy to school age 
globally means this is now within our grasp1. 
 
The fact that sub-optimal fetal growth places the baby at increased risk of stillbirth and fetal distress in 
labour has been shown in numerous studies; in his thought-provoking article Bob Silver explains the 
link between the fetus that is small for gestational age (below a certain percentile of size) and stillbirth. 
He examines this link in light of recent relevant data that suggest that there may be some bias at play; 
this is because there is weight loss of a baby between death in utero and being weighed at birth; and 
also due to the time-lag between these two events. He concludes that here is no doubt that there 
remains an association, probably causative, between poor fetal growth and adverse outcome; but that 
such bias may artificially strengthen this association. Clearly further detailed research is needed to 
understand the implications of this.  
 
What is also clear is that estimating the size of the fetus prenatally is a prerequisite for the diagnosis 
of growth aberrations; for the most part, the tool used for this is ultrasound. The excellent article by 
Neil O'Gorman and Laurent Salomon explains how such assessment should best be undertaken; it 
includes the crucial aspect of gestational age estimation, without which interpretation of 
appropriateness of size for gestation is impossible. The chapter also covers concepts such as using 
interval fetal growth; but also novel imaging modalities such as 3D ultrasound and MRI. Despite these 
advances in imaging the fetus, Gordon Smith makes the important point that current evidence is not 
conclusive as to whether universal late pregnancy ultrasound does more harm or more good; the data 
are suggestive, but ultimately inconclusive. It must also be said that in large parts of the world 
ultrasound is not available meaning that gestational age estimation and fetal assessment has to be 
undertaken clinically. Sikolia Wanyonyi and Steve Mutiso share their experience on how this impacts 
diagnosis and management of growth restriction in low resource setting and what strategies are 
required to improve this situation. A particular scenario of increased risk of growth abnormalities is in 
twin pregnancy. Rosie Townsend and Asma Khalil share their insights into the specific issues 
concerning how diagnosis and particular management differ in this setting. 
  
One of the principles of screening that Wilson and Jungner defined in 1968, is that there should be an 
accepted treatment 2. In the context of fetal growth restriction, currently this is indicated early birth of 
the baby; Aamod Nawathe and Anna David review all current preventative or treatment modalities 
that may ameliorate growth restriction due to poor placental function, and point out the most 
promising opportunities. 
  
The manifestation of growth restriction in the fetus is a series adaptions to the in-utero environment 
through endocrine, metabolic and cardiovascular changes. These are described in outstanding detail 
by Karel Marsal. It is through measurement of these physiological parameters using ultrasound (but 
also increasingly using biomarkers) that allows us to fine tune our management. These 
measurements help the clinician, who is faced with a number of questions: what is the cause of the 
growth pattern seen? when should I review this patient? and when should I deliver the poorly growing 
baby? Ahmed Baschat’s description of a uniform approach to management, shows how outcomes 
can be improved in both early and late onset growth restriction by carefully balancing the benefits of 
advancing gestational age versus the ever impending risks of stillbirth. Once the baby is born, there is 
a critical opportunity for postnatal growth and development and the chapter by Bianca Carducci and 
Zulfi Bhutta outlines how specialist care of such high-risk newborns is necessary in order to overcome 
particular challenges, such as those of poor thermoregulation, how to provide correct nutrition and 
indeed how to monitor growth postnatally. 
  
Finally there is an important chapter on how we can use consensus. A great deal of evidence can be 
gained in medicine by data synthesis. In very simple terms, many small studies can be amalgamated 
to reach larger samples and more robust estimates. But this is often difficult to achieve as many 
studies use different definitions, measurements and outcomes. Take as an example the commonly 
used term “intrauterine growth restriction”, often defined as the inability of the fetus to achieve its 
genetic growth potential. But as genetic growth potential is not currently a definable characteristic, 
how can we define its absence? For this reason, consensus, based on the opinion of many individual 
contributors, can take the field forward - although it must always be remembered that the fetus is not 
taking part in these consensus procedures. Sanne Gordijn, Irene Beune and Wessel Ganzevoort, give 
us their view on the advantages and pitfalls of this approach. 
  
It has been a privilege to work with the world’s foremost experts on this issue of Best Practice & 
Research: Clinical Obstetrics & Gynaecology. The end result is a series of articles of remarkable 
quality. It should keep you busy reading this journal from cover to cover, and I am confident you will 
enjoy reading it as much as I enjoyed editing it! 
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